cerca CERCA
Lunedì 01 Marzo 2021
Aggiornato: 17:22
Temi caldi


Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member

FREIBURG, Germany, Jan. 6, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to its Executive Board.

ora in
Prima pagina
in Evidenza